Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04638647 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04638647 · ClinicalTrials.gov record · last posted 2026-08-18

Secukinumab Open Label Roll-over Extension Protocol

Name: Secukinumab Open Label Roll-over Extension Protocol — clinical trial record (NCT04638647)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorNovartis Pharmaceuticals

Started2020-12-22

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.

Amendment record 60 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 60 times since 2020-11-16; most recent amendment 2026-07-07. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2021-01-15

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT04638647
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Autoimmunity, Inflammation
Enrollment	1,000 participants
Start Date	2020-12-22
Primary Completion	2030-01-29 (estimated)
Study Completion	2030-04-04 (estimated)
Updated on ClinicalTrials.gov	2026-08-18